Healthcare technology firm Schrödinger LLC raised a total of $110 million from existing and new investors to fund its computational platform and the expansion of its therapeutic pipeline.

Invus Group LLC, Pavilion Capital Partners LLC, Laurion Capital Management LP, Oculus co-founder Michael Antonov's Tubus Management fund and other new investors participated in the funding round, alongside existing investors Bill and Melinda Gates Foundation Trust, WuXi AppTec Co. Ltd.'s Corporate Venture Fund, Deerfield Management Co. LP, Baron Capital Group Inc., Qiming Venture Partners LLC and Google Ventures.

Schrödinger's platform is used by pharmaceutical, biotechnology, chemical and electronics companies for research and development in drug discovery and materials design, according to a release.